Cite

    Susanna Bianzano et al.. “Safety, tolerability, pharmacodynamics and pharmacokinetics following once‐daily doses of BI 187004, an inhibitor of 11 beta‐hydroxysteroid dehydrogenase‐1, over 28 days in patients with type 2 diabetes mellitus and overweight or obesity.” Diabetes, obesity & metabolism, vol. 25, no. 3, 2023, pp. 832–843. http://access.bl.uk/ark:/81055/vdc_100177560021.0x000036